DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

the treatment of patients with recurrent, hemodynamically
destabilizing ventricular tachycardia or fibrillation. The
Intravenous Amiodarone Multicenter Investigators Group.
Circulation, 1995, 92:3255–3263.
Krapivinsky G, Gordon EA, Wickman K, et al. The G protein–
gated atrial K + channel I KACh
is a heteromultimer of two
inwardly rectifying K + -channel proteins. Nature, 1995, 374:
135–141.
Kroemer HK, Turgeon J, Parker RA, Roden DM. Flecainide enantiomers:
Disposition in human subjects and electrophysiologic
actions in vitro. Clin Pharmacol Ther, 1989, 46:584–590.
Kurokawa J, Suzuki T, Furukawa T. New aspects for the treatment
of cardiac diseases based on the diversity of functional
controls on cardiac muscles: Acute effects of female hormones
on cardiac ion channels and cardiac repolarization. J Pharmacol
Sci, 2009, 109:334–340.
Lee JH, Rosen MR. Use-dependent actions and effects on transmembrane
action potentials of flecainide, encainide, and ethmozine
in canine Purkinje fibers. J Cardiovasc Pharmacol,
1991, 18:285–292.
Lee JT, Kroemer HK, Silberstein DJ, et al. The role of genetically
determined polymorphic drug metabolism in the betablockade
produced by propafenone. N Engl J Med, 1990,
322:1764–1768.
Lerman BB, Belardinelli L. Cardiac electrophysiology of adenosine:
Basic and clinical concepts. Circulation, 1991,
83:1499–1509.
Levine JH, Moore EN, Kadish AH, et al. Mechanisms of
depressed conduction from long-term amiodarone therapy in
canine myocardium. Circulation, 1988, 78:684–691.
Levy S, Azoulay S. Stories about the origin of quinquina and
quinidine. J Cardiovasc Electrophysiol, 1994, 5:635–636.
Lie KI, Wellens HJ, van Capelle FJ, Durrer D. Lidocaine in the
prevention of primary ventricular fibrillation: A double-blind,
randomized study of 212 consecutive patients. N Engl J Med,
1974, 291:1324–1326.
Lima JJ, Boudoulas H, Blanford M. Concentration-dependence
of disopyramide binding to plasma protein and its influence
on kinetics and dynamics. J Pharmacol Exp Ther, 1981, 219:
741–747.
MacKinnon R. Potassium channels. FEBS Lett, 2003, 555:
62–65.
Mao ZL, Wheeler JJ, Clohs L, et al. Pharmacokinetics of novel
atrial-selective antiarrhythmic agent vernakalant hydrochloride
injection (RSD1235): Influence of CYP2D6 expression
and other factors. J Clin Pharmacol, 2009, 49:17–29.
Mason JW. A comparison of seven antiarrhythmic drugs in
patients with ventricular tachyarrhythmias. Electrophysiologic
Study versus Electrocardiographic Monitoring Investigators.
N Engl J Med, 1993, 329:452–458.
Mason JW. Amiodarone. N Engl J Med, 1987, 316:455–466.
Mitcheson JS, Chen J, Lin M, et al. A structural basis for druginduced
long QT syndrome. Proc Natl Acad Sci USA, 2000,
97:12329–12333.
Mohamed U, Napolitano C, Prioiri SG. Molecular and electrophysiological
basis of catecholaminergic polymorphic ventricular
tachycardia. J Cardiovasc Electrophysiol, 2007, 18:
791–797.
Morady F, Scheinman MM, Desai J. Disopyramide. Ann Intern
Med, 1982, 96:337–343.
Murray KT. Ibutilide. Circulation, 1998, 97:493–497.
Myerburg RJ, Kessler KM, Cox MM, et al. Reversal of proarrhythmic
effects of flecainide acetate and encainide hydrochloride
by propranolol. Circulation, 1989, 80:1571–1579.
Napolitano C, Bloise R, Priori S. Gene-specific therapy for
inherited arrhythmogenic diseases. Pharmacol Ther, 2006,
100:1–13.
Nerbonne JM, Kass RS. Molecular physiology of cardiac repolarization.
Physiol Rev, 2005, 85:1205–1253.
Nies AS, Shand DG, Wilkinson GR. Altered hepatic blood flow
and drug disposition. Clin Pharmacokinet, 1976, 1:135–155.
Patel C, Yan GX, Kowey PR. Dronedarone. Circulation, 2009,
120:636–644.
Podrid PJ, Schoeneberger A, Lown B. Congestive heart failure
caused by oral disopyramide. N Engl J Med, 1980, 302:
614–617.
Priori SG, Barhanin J, Hauer RN, et al. Genetic and molecular
basis of cardiac arrhythmias: Impact on clinical management.
Study Group on Molecular Basis of Arrhythmias of the
Working Group on Arrhythmias of the European Society of
Cardiology. Eur Heart J, 1999, 20:174–195.
Roden DM. Antiarrhythmic drugs: Past, present and future.
J Cardiovasc Electrophysiol, 2003, 14:1389–1396.
Roden DM. Current status of class III antiarrhythmic drug
therapy. Am J Cardiol, 1993, 72:44B–49B.
Roden DM. Drug-induced prolongation of the QT interval.
N Engl J Med, 2004, 350:1013–1022.
Roden DM. Risks and benefits of antiarrhythmic therapy. N Engl
J Med, 1994, 331:785–791.
Roden DM, Echt DS, Lee JT, Murray KT. Clinical pharmacology
of antiarrhythmic agents. In: Josephson ME, ed. Sudden
Cardiac Death. Blackwell Scientific, London, 1993, pp.
182–185.
Roden DM, Woosley RL. Drug therapy: Flecainide. N Engl J
Med, 1986, 315:36–41.
Roy D, Pratt CM, Torp-Pedersen C, et al. Vernakalant hydrochloride
for rapid conversion of atrial fibrillation: A phase 3,
randomized, placebo-controlled trial. Circulation, 2008, 117:
1518–1525.
Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence
of atrial fibrillation. Canadian Trial of Atrial Fibrillation
Investigators. N Engl J Med, 2000, 342:913–920.
Ruskin JN. The Cardiac Arrhythmia Suppression Trial (CAST).
N Engl J Med, 1989, 321:386–388.
Sanguinetti MC, Jurkiewicz NK. Two components of cardiac
delayed rectifier K + current: Differential sensitivity to block by
class III antiarrhythmic agents. J Gen Physiol, 1990, 96: 195–215.
Sanguinetti MC, Jurkiewicz NK, Scott A, Siegl PK.
Isoproterenol antagonizes prolongation of refractory period by
the class III antiarrhythmic agent E-4031 in guinea pig
myocytes: Mechanism of action. Circ Res, 1991, 68:77–84.
Schwartz PJ, Priori SG, Napolitano C. Long QT syndrome. In:
Zipes DP, Jalife J, eds. Cardiac Electrophysiology: From Cell
to Bedside, 3rd ed. Saunders, Philadelphia, 2000, pp. 615–640.
Singer DE. Anticoagulation for atrial fibrillation: Epidemiology
informing a difficult clinical decision. Proc Assoc Am Phys,
1996, 108:29–36.
Singh BN. Advantages of beta blockers versus antiarrhythmic
agents and calcium antagonists in secondary prevention after
myocardial infarction. Am J Cardiol, 1990, 66:9C–20C.
Smith TW. Digitalis: Mechanisms of action and clinical use.
N Engl J Med, 1988, 318:358–365.
847
CHAPTER 29
ANTI-ARRHYTHMIC DRUGS